Clinical Research Directory
Browse clinical research sites, groups, and studies.
Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
Sponsor: Hospital de Clinicas de Porto Alegre
Summary
Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2002-02
Completion Date
2032-12
Last Updated
2016-11-01
Healthy Volunteers
No
Interventions
Immediate-release Methylphenidate
Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects
Locations (1)
Program on Attention-Deficit/Hyperactivity Disorder (PRODAH); Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil